Cargando…

Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure

Background: Recent studies have linked histone deacetylases (HDAC) to remodeling of the heart and cardiac fibrosis in heart failure. However, the molecular mechanisms linking chromatin remodeling events with observed anti-fibrotic effects are unknown. Here, we investigated the molecular players invo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nural-Guvener, Hikmet, Zakharova, Liudmila, Feehery, Lorraine, Sljukic, Snjezana, Gaballa, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463712/ https://www.ncbi.nlm.nih.gov/pubmed/25997003 http://dx.doi.org/10.3390/ijms160511482

Ejemplares similares

HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
por: Nural-Guvener, Hikmet F, et al.
Publicado: (2014)

Chronic Heart Failure Is Associated With Transforming Growth Factor Beta‐Dependent Yield and Functional Decline in Atrial Explant‐Derived c‐Kit+ Cells
por: Zakharova, Liudmila, et al.
Publicado: (2013)

Cardiac Explant-Derived Cells Are Regulated by Notch-Modulated Mesenchymal Transition
por: Zakharova, Liudmila, et al.
Publicado: (2012)

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
por: Meidhof, Simone, et al.
Publicado: (2015)

Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6
por: Zhang, Q, et al.
Publicado: (2016)

Profile of Class I Histone Deacetylases (HDAC) by Human Dendritic Cells after Alcohol Consumption and In Vitro Alcohol Treatment and Their Implication in Oxidative Stress: Role of HDAC Inhibitors Trichostatin A and Mocetinostat
por: Agudelo, Marisela, et al.
Publicado: (2016)

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
por: Lopez, Gonzalo, et al.
Publicado: (2017)

Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis
por: Kawata, Manabu, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids
por: Karandish, Fataneh, et al.
Publicado: (2016)

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)

Class IIa HDACs in myelination
por: Velasco-Aviles, Sergio, et al.
Publicado: (2018)

In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting
por: Kaya Çakir, Hacer, et al.
Publicado: (2021)

The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
por: Kim, Young-Suk, et al.
Publicado: (2019)

Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2
por: Segré, Chiara V., et al.
Publicado: (2011)

The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms
por: Liu, Jia, et al.
Publicado: (2023)

Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment
por: Kasembeli, Moses M., et al.
Publicado: (2018)

The Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms
por: Li, Yanxia, et al.
Publicado: (2022)

Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion
por: Dresselhaus, Erica, et al.
Publicado: (2018)

HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies
por: Yan, Bing, et al.
Publicado: (2017)

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
por: Choy, Edwin, et al.
Publicado: (2018)

Disruption of Intranasal GnRH Neuronal Migration Route into the Brain Induced by Proinflammatory Cytokine IL-6: Ex Vivo and In Vivo Rodent Models
por: Sharova, Viktoria, et al.
Publicado: (2023)

Specific Control of Pancreatic Endocrine β- and δ-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9
por: Lenoir, Olivia, et al.
Publicado: (2011)

Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling
por: Jiang, Ruiyuan, et al.
Publicado: (2023)

HDAC4 in ischemic stroke: mechanisms and therapeutic potential
por: Kong, Qingsheng, et al.
Publicado: (2018)

Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation
por: Lei, Yubin, et al.
Publicado: (2017)

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
por: Choy, Edwin, et al.
Publicado: (2019)

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
por: Nebbioso, Angela, et al.
Publicado: (2009)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Discovering HDAC class II selective inhibitors by multidisciplinary approach
por: Lorenzi, S, et al.
Publicado: (2011)

Physiological Roles of Class I HDAC Complex and Histone Demethylase
por: Hayakawa, Tomohiro, et al.
Publicado: (2011)

Class II and IV HDACs function as inhibitors of osteoclast differentiation
por: Blixt, Nicholas C., et al.
Publicado: (2017)

Ring size changes in the development of class I HDAC inhibitors
por: Cho, Er-Chieh, et al.
Publicado: (2021)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

MiR‐22‐3p inhibits fibrotic cataract through inactivation of HDAC6 and increase of α‐tubulin acetylation
por: Wang, Xiaoran, et al.
Publicado: (2020)

JAK-STAT Pathway Inhibition Partially Restores Intestinal Homeostasis in Hdac1- and Hdac2-Intestinal Epithelial Cell-Deficient Mice
por: Gonneaud, Alexis, et al.
Publicado: (2021)

STAT transcription in the ischemic heart
por: Knight, Richard A., et al.
Publicado: (2012)

Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
por: Jayathilaka, Nimanthi, et al.
Publicado: (2012)

Insights into the activation mechanism of class I HDAC complexes by inositol phosphates
por: Watson, Peter J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hvfc308dih5qo5a20lv7mic9e7